Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus

Lupus

Volumn 25, Issue 6, 2016, Pages 582-592

  Salazar Camarena, D C ^a   Ortiz Lazareno, P C ^b   Cruz, A ^a   Oregon Romero, E ^a   Machado Contreras, J R ^a   Munoz Valle J F ^a   Orozco Lopez M ^a   Marin Rosales M ^a   Palafox Sánchez, Claudia Azucena ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

B cell subsets; BAFF; BAFF receptors; BAFF R; BCMA; disease activity; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; APRIL PROTEIN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TNFRSF13B PROTEIN, HUMAN; TNFRSF17 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HEMOLYTIC ANEMIA; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; B LYMPHOCYTE SUBPOPULATION; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-CELL MATURATION ANTIGEN; B-LYMPHOCYTE SUBSETS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 84963542514     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315608254     Document Type: Article

References (46)

1. Mackay F, Schneider P,. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491-502.
2. Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24: 203-215.
3. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-2111.
4. Schneider P,. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17: 282-289.
5. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201: 35-39.
6. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010; 11: 836-845.
7. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-98.
8. Abu-Rish EY, Amrani Y, Browning MJ,. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. Rheumatology (Oxford) 2013; 52: 190-201.
9. Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065-1067.
10. Becker-Merok A, Nikolaisen C, Nossent HC,. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15: 570-576.
11. Zhang J, Roschke V, Baker KP, et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
12. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-39.
13. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.
14. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002; 109: 59-68.
15. Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007; 56: 1134-1144.
16. Candon S, Gottenberg JE, Bengoufa D, Chatenoud L, Mariette X,. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: Correlation with B-cell biomarkers and disease activity. Ann Rheum Dis 2009; 68: 1208-1212.
17. Alsaleh G, Messer L, Semaan N, et al. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 2007; 56: 3202-3214.
18. Moura RA, Canhão H, Polido-Pereira J, et al. BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. J Rheumatol 2013; 40: 1293-1302.
19. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-2459.
20. George-Chandy A, Trysberg E, Eriksson K,. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: Relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10: R97-R97.
21. Sanz I, Yasothan U, Kirkpatrick P,. Belimumab. Nat Rev Drug Discov 2011; 10: 335-336.
22. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
23. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930.
24. Carter RH, Zhao H, Liu X, et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3943-3954.
25. Darce JR, Arendt BK, Wu X, et al. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007; 179: 7276-7286.
26. Zhao LD, Li Y, Smith MF, et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010; 19: 1534-1549.
27. Kim J, Gross JA, Dillon SR, et al. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation. Autoimmunity 2011; 44: 69-81.
28. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
29. Guzmán J, Cardiel MH, Arce-Salinas A, et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
30. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
31. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-5979.
32. Hostmann A, Jacobi AM, Mei H, Hiepe F, et al. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 2008; 17: 1064-1069.
33. Cheng Q, Mumtaz IM, Khodadadi L, et al. Autoantibodies from long-lived "memory" plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis 2013; 72: 2011-2017.
34. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332-1342.
35. Dörner T, Lipsky PE,. Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus 2004; 13: 283-289.
36. Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007; 178: 6624-6633.
37. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58: 1762-1773.
38. Sellam J, Miceli-Richard C, Gottenberg JE, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 790-797.
39. Zhang M, Ko KH, Lam QL, et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 2005; 17: 1081-1092.
40. Cancro MP,. Signalling crosstalk in B cells: Managing worth and need. Nat Rev Immunol 2009; 9: 657-661.
41. Koarada S, Tada Y, Suematsu R,. Phenotyping of P105-negative B cells subsets in patients with systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 198206-198206.
42. Coquery CM, Loo WM, Wade NS, et al. BAFF regulates T follicular helper cells and affects accumulation and IFNγ production in autoimmunity. Arthritis Rheumatol 2015; 67: 773-784.
43. Jiang C, Loo WM, Greenley EJ, et al. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol 2011; 186: 136-147.
44. Hegazy M, Darwish H, Darweesh H, et al. Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices. Clin Immunol 2010; 135: 118-124.
45. Boghdadi G, Elewa EA,. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int 2014; 34: 1217-1223.
46. Treamtrakanpon W, Tantivitayakul P, Benjachat T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther 2012; 14: R252-R252.